RxDoctor Payments Data

Adrienne Feasel, MD

Dermatology · Austin, TXNPI 1982664447

Payments from drug & device makers

$14,853in general payments, 2019–2025

Across 865 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Novartis$2K
  • Pfizer$1K
  • Sun Pharmaceutical Industries Inc.$982
  • Regeneron Healthcare Solutions, Inc.$785
  • plus $7K from 28 others

What the payments were for

  • Consulting fees$3502%
  • Speaking & faculty fees$1501%
  • Food & beverage$13,84993%
  • Education$5043%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,853 in reported general payments places this provider in the 75th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$349,610
Medicare patients
742
Services billed
6,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib22$147,394
Taltz AutoinjectorIxekizumab16$110,294
Cosentyx Sensoready (2 Pens)Secukinumab12$88,688
Ivermectin15$2,951
Doxycycline Hyclate49$2,828
Metronidazole36$1,781
Clobetasol Propionate43$1,751
Tretinoin20$1,254
Fluorouracil20$1,014
ValacyclovirValacyclovir Hcl41$969
Ketoconazole44$837
Betamethasone Dipropionate21$783
Doxycycline Monohydrate23$701
Minoxidil74$611
Fluocinonide15$527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,845$147,39422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →